Why is Brawn Biotech falling/rising?

As of 30-Jun, Brawn Biotech Ltd's stock price is currently at 17.48, reflecting an increase of 0.83 or 4.98%. The stock has been gaining momentum recently, with a consecutive gain over the last two days, resulting in an overall return of 8.17% during this period. However, despite this short-term rise, the stock has underperformed in the longer term, with a year-to-date decline of 17.97% and a significant drop of 33.26% over the past year. The company's financial health is concerning, as it has reported operating losses and a weak ability to service its debt, which negatively impacts investor sentiment. Additionally, the stock's liquidity is adequate for trading, but a drastic fall in delivery volume indicates declining investor participation.
In the broader market context, Brawn Biotech's recent performance has outpaced its sector by 2.59%, but it still lags behind the benchmark Sensex, which has shown a positive return of 2.09% over the past week. While the stock's short-term gains may attract some attention, its long-term fundamentals remain weak, with poor growth rates in net sales and operating profit. This combination of short-term performance and long-term challenges suggests that while the stock may be experiencing a brief rise, the underlying issues could lead to continued volatility and potential declines in the future.